Factors associated with triptan use in episodic migraine: Results from the American migraine prevalence and prevention study

Min Kyung Chu, Dawn C. Buse, Marcelo E. Bigal, Daniel Serrano, Richard B. Lipton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatment. Objective. To assess the sociodemographic and headache features associated with triptan use in a US population sample of persons with episodic migraine. Methods. The American Migraine Prevalence and Prevention Study (AMPP) is a longitudinal study conducted in a representative sample of US headache sufferers. Episodic migraineurs (n = 11,388) who provided treatment data in 2005 were included in the current analyses. We assessed factors associated with triptan use through univariate and multivariate analyses. Multivariate analyses were adjusted for sociodemographic factors, headache-related disability, cutaneous allodynia, depression, and preventive headache medication use. Results. Among persons with episodic migraine, 18.31% reported current use of triptans for acute headache treatment. In univariate analyses, triptan use was most common in midlife (ages 30-59), among females, and was more common in Caucasians than in African Americans. Triptan use increased with headache frequency, headache-related disability and allodynia, but decreased among persons with depression. In multivariate analyses, female gender, Caucasian race, age 40-49, higher levels of education (college or higher), annual household income of ≤ $40,000, having health insurance, the presence of cutaneous allodynia, greater headache-related disability, and preventive medication use for migraine were significantly associated with triptan use. Conclusions. Less than 1 in 5 persons with migraine in the United States who were respondents to this survey used triptans for acute headache treatment over the course of a year. Several markers of severe headache, including disability and allodynia, were associated with increased triptan use. Groups less likely to get triptans included males, African Americans, older adults, and the uninsured. Predictors of use provide insight into groups with unmet treatment needs.

Original languageEnglish (US)
Pages (from-to)213-223
Number of pages11
JournalHeadache
Volume52
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Tryptamines
Migraine Disorders
Headache
Cross-Sectional Studies
Hyperalgesia
Multivariate Analysis
African Americans
Therapeutics
Depression
Skin
Health Insurance
Longitudinal Studies

Keywords

  • acute treatment
  • depression
  • headache-related disability
  • migraine
  • preventive treatment
  • triptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Factors associated with triptan use in episodic migraine : Results from the American migraine prevalence and prevention study. / Chu, Min Kyung; Buse, Dawn C.; Bigal, Marcelo E.; Serrano, Daniel; Lipton, Richard B.

In: Headache, Vol. 52, No. 2, 02.2012, p. 213-223.

Research output: Contribution to journalArticle

Chu, Min Kyung ; Buse, Dawn C. ; Bigal, Marcelo E. ; Serrano, Daniel ; Lipton, Richard B. / Factors associated with triptan use in episodic migraine : Results from the American migraine prevalence and prevention study. In: Headache. 2012 ; Vol. 52, No. 2. pp. 213-223.
@article{75a0052f3bed4ccb92e6e011aedec0ee,
title = "Factors associated with triptan use in episodic migraine: Results from the American migraine prevalence and prevention study",
abstract = "Background: Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatment. Objective. To assess the sociodemographic and headache features associated with triptan use in a US population sample of persons with episodic migraine. Methods. The American Migraine Prevalence and Prevention Study (AMPP) is a longitudinal study conducted in a representative sample of US headache sufferers. Episodic migraineurs (n = 11,388) who provided treatment data in 2005 were included in the current analyses. We assessed factors associated with triptan use through univariate and multivariate analyses. Multivariate analyses were adjusted for sociodemographic factors, headache-related disability, cutaneous allodynia, depression, and preventive headache medication use. Results. Among persons with episodic migraine, 18.31{\%} reported current use of triptans for acute headache treatment. In univariate analyses, triptan use was most common in midlife (ages 30-59), among females, and was more common in Caucasians than in African Americans. Triptan use increased with headache frequency, headache-related disability and allodynia, but decreased among persons with depression. In multivariate analyses, female gender, Caucasian race, age 40-49, higher levels of education (college or higher), annual household income of ≤ $40,000, having health insurance, the presence of cutaneous allodynia, greater headache-related disability, and preventive medication use for migraine were significantly associated with triptan use. Conclusions. Less than 1 in 5 persons with migraine in the United States who were respondents to this survey used triptans for acute headache treatment over the course of a year. Several markers of severe headache, including disability and allodynia, were associated with increased triptan use. Groups less likely to get triptans included males, African Americans, older adults, and the uninsured. Predictors of use provide insight into groups with unmet treatment needs.",
keywords = "acute treatment, depression, headache-related disability, migraine, preventive treatment, triptan",
author = "Chu, {Min Kyung} and Buse, {Dawn C.} and Bigal, {Marcelo E.} and Daniel Serrano and Lipton, {Richard B.}",
year = "2012",
month = "2",
doi = "10.1111/j.1526-4610.2011.02032.x",
language = "English (US)",
volume = "52",
pages = "213--223",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Factors associated with triptan use in episodic migraine

T2 - Results from the American migraine prevalence and prevention study

AU - Chu, Min Kyung

AU - Buse, Dawn C.

AU - Bigal, Marcelo E.

AU - Serrano, Daniel

AU - Lipton, Richard B.

PY - 2012/2

Y1 - 2012/2

N2 - Background: Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatment. Objective. To assess the sociodemographic and headache features associated with triptan use in a US population sample of persons with episodic migraine. Methods. The American Migraine Prevalence and Prevention Study (AMPP) is a longitudinal study conducted in a representative sample of US headache sufferers. Episodic migraineurs (n = 11,388) who provided treatment data in 2005 were included in the current analyses. We assessed factors associated with triptan use through univariate and multivariate analyses. Multivariate analyses were adjusted for sociodemographic factors, headache-related disability, cutaneous allodynia, depression, and preventive headache medication use. Results. Among persons with episodic migraine, 18.31% reported current use of triptans for acute headache treatment. In univariate analyses, triptan use was most common in midlife (ages 30-59), among females, and was more common in Caucasians than in African Americans. Triptan use increased with headache frequency, headache-related disability and allodynia, but decreased among persons with depression. In multivariate analyses, female gender, Caucasian race, age 40-49, higher levels of education (college or higher), annual household income of ≤ $40,000, having health insurance, the presence of cutaneous allodynia, greater headache-related disability, and preventive medication use for migraine were significantly associated with triptan use. Conclusions. Less than 1 in 5 persons with migraine in the United States who were respondents to this survey used triptans for acute headache treatment over the course of a year. Several markers of severe headache, including disability and allodynia, were associated with increased triptan use. Groups less likely to get triptans included males, African Americans, older adults, and the uninsured. Predictors of use provide insight into groups with unmet treatment needs.

AB - Background: Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatment. Objective. To assess the sociodemographic and headache features associated with triptan use in a US population sample of persons with episodic migraine. Methods. The American Migraine Prevalence and Prevention Study (AMPP) is a longitudinal study conducted in a representative sample of US headache sufferers. Episodic migraineurs (n = 11,388) who provided treatment data in 2005 were included in the current analyses. We assessed factors associated with triptan use through univariate and multivariate analyses. Multivariate analyses were adjusted for sociodemographic factors, headache-related disability, cutaneous allodynia, depression, and preventive headache medication use. Results. Among persons with episodic migraine, 18.31% reported current use of triptans for acute headache treatment. In univariate analyses, triptan use was most common in midlife (ages 30-59), among females, and was more common in Caucasians than in African Americans. Triptan use increased with headache frequency, headache-related disability and allodynia, but decreased among persons with depression. In multivariate analyses, female gender, Caucasian race, age 40-49, higher levels of education (college or higher), annual household income of ≤ $40,000, having health insurance, the presence of cutaneous allodynia, greater headache-related disability, and preventive medication use for migraine were significantly associated with triptan use. Conclusions. Less than 1 in 5 persons with migraine in the United States who were respondents to this survey used triptans for acute headache treatment over the course of a year. Several markers of severe headache, including disability and allodynia, were associated with increased triptan use. Groups less likely to get triptans included males, African Americans, older adults, and the uninsured. Predictors of use provide insight into groups with unmet treatment needs.

KW - acute treatment

KW - depression

KW - headache-related disability

KW - migraine

KW - preventive treatment

KW - triptan

UR - http://www.scopus.com/inward/record.url?scp=84857051480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857051480&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2011.02032.x

DO - 10.1111/j.1526-4610.2011.02032.x

M3 - Article

C2 - 22413150

AN - SCOPUS:84857051480

VL - 52

SP - 213

EP - 223

JO - Headache

JF - Headache

SN - 0017-8748

IS - 2

ER -